摘要
目的:系统评价辅助化疗联合曲妥珠单抗治疗人表皮生长因子受体-2(HER2)阳性晚期或转移性乳腺癌的临床效果。方法:检索国内外公开发表的关于辅助化疗联合曲妥珠单抗治疗HER2阳性晚期或转移性乳腺癌的中英文文献,对纳入的研究进行比较。结果:共纳入6篇随机对照试验(RCT)研究。辅助化疗联合曲妥珠单抗治疗HER2阳性晚期或转移性乳腺癌的反应率和病理完全缓解率的风险比(RR)分别为1.46(P=0.02)和0.98(P=0.91)。结论:尽管研究存在一定的局限性,但在不考虑治疗成本的情况下,辅助化疗联合曲妥珠单抗治疗要优于标准治疗,临床上具有较强的可替代性。
OBJECTIVE： To evaluate the clinical efficacy of trastuzunlab plus adjuvant chemotherapy for advanced or metastatic breast cancer in patients with positive human epidermal growth factor receptor-2 （HER-2）. METHODS ： We retrieved the literature both in Chinese arid in English about trastuzumab plus adjuvant chemotherapy for treatment of advanced or metastatic breast cancer in patients with positive HER-2 and compared the studies included. RESULTS： A total of six randomized controlled trials （RCTs） were included. The RR value of response rate and pathologic complete response rate stood at 1.46 （ P=0.02 ） and 0.98 （ P = 0.91 ）, respectively in HER-2 positive advanced or metastatic breast cancer patients treated with trastuzumab plus adjuvant chemotherapy. CONCLUSION： Although the studies have limitation, yet if without considering the treatment cost, trastuzumab plus adjuvant chemotherapy is superior to the standard treatment and it has strong substitutability clinically.
出处
《中国医院用药评价与分析》
2013年第6期497-500,共4页
Evaluation and Analysis of Drug-use in Hospitals of China
关键词
辅助化疗
曲妥珠单抗
乳腺癌
Adjuvant chemotherapy
Trastuzumab
Breast cancer
